DeepNiche

Alzheimer's

Ascendiant lifts IGC 12-month target to $6

The firm maintained a BUY rating on NYSE American: IGC.

source: IGC Pharma

Get DeepNiche

The full briefing is in the app.

More Alzheimer's clippings